Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 4, 2009, Pages 403-414

  Roke, Yvette ^a   Van Harten, Peter N ^a   Boot, Annemieke M ^b   Buitelaar, Jan K ^c  

^a Psychiatric Center   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; AUTISM; BIPOLAR DISORDER; BONE DENSITY; CHILD; CONDUCT DISORDER; DEPRESSION; DESCRIPTIVE RESEARCH; DISRUPTIVE BEHAVIOR; GALACTORRHEA; GENETIC DIFFERENCE; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; MAINTENANCE THERAPY; MENSTRUAL IRREGULARITY; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; PUBERTY; QUESTIONNAIRE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; GYNECOMASTIA; HUMANS; HYPERPROLACTINEMIA; MALE; PROLACTIN; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 69549086733     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0120     Document Type: Review

References (86)

1. Abraham G, Halbreich U, Friedman RH, Josiassen RC: Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 59:17-18, 2003a. (Pubitemid 35284489)
2. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC: Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am J Psychiatry 160:1618-1620, 2003b. (Pubitemid 41079547)
3. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M: Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12:83-91, 2002. (Pubitemid 34779022)
4. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002. (Pubitemid 34832715)
5. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E: Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545-550, 2007. (Pubitemid 46185331)
6. Arango C, Parellada M, Moreno DM: Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 14(Suppl 4):S471-S479, 2004. (Pubitemid 39574339)
7. Becker AL, Epperson CN: Female puberty: Clinical implications for the use of prolactin-modulating psychotropics. Child Adolesc Psychiatr Clin N Am 15:207-220, 2006.
8. Bembo SA, Carlson HE: Gynecomastia: Its features, and when and how to treat it. Cleve Clin J Med 71:511-517, 2004. (Pubitemid 38832615)
9. Bevan JS: Interpreting prolactin levels: Implications for the management of large pituitary lesions. Br J Neurosurg 5:3-6, 1991.
10. Blaicher W, Imhof MH, Gruber DM, Schneeberger C, Sator MO, Huber JC: Endocrinological disorders. Focusing on melatonin's interactions. Gynecol Obstet Invest 48:179-182, 1999.
11. Bobes J, Garc APMP, Rejas J, Hernandez G, Garcia-Garcia M, Rico-Villademoros F: Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther 29:125-147, 2003. (Pubitemid 36278732)
12. Buckley PF: Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50:912-924, 2001. (Pubitemid 34020702)
13. Byerly M, Suppes T, Tran QV, Baker RA: Clinical implications of antipsychotic-induced hyperprolactinaemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. J Clin Psychopharmacol 27:639-661, 2007 (Pubitemid 351339452)
14. Carter DA, McGarrick GM, Norton KR, Paykel ES, Prysor-Jones RA, Whitehead SA: The effect of chronic neuroleptic treatment on gonadotrophin release. Psychoneuroendocrinology 7:201-207, 1982.
15. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R: Prolactinomas in adolescents: Persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf ) 52:319-327, 2000. (Pubitemid 30169688)
16. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA: New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753-759, 2004. (Pubitemid 39025073)
17. Correll CU: Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20, 2008a.
18. Correll CU: Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry, 20:195-201, 2008b.
19. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics:Asystematic review of 1-year studies. Am J Psychiatry 161:414-425, 2004. (Pubitemid 38326094)
20. Costa AM, de Lima MS, Faria M, Filho SR, de Oliveira IR, de Jesus Mari J: A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol 21:165-170, 2007. (Pubitemid 46280467)
21. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S: Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64-72, 2005. (Pubitemid 40019201)
22. Davies JH, Evans BA, Gregory JW: Bone mass acquisition in healthy children. Arch Dis Child 90:373-378, 2005.
23. Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J: Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: Results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 18:54-69, 2008. (Pubitemid 351311238)
24. Dolder CR, Lacro JP, Dunn LB, Jeste DV: Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108, 2002.
25. Duval F, Guillon MS, Mokrani MC, Crocq MA, Garcia Duarte, F: Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. Psychoneuroendocrinology 33:255-259, 2008.
26. Fegert JM, Findling RL, deSmedt G: Risperidon zur Behandlung aggressiv-impulsiven Verhaltens bei Kindern und Jugendlichen mit Intelligenz im unteren Durchschnittsbereich, Lernbehinderung und leichter geistiger Behinderung. [Risperidone in children and adolescents with disruptive behavior disorders, learning disorders and subaverage intelligence.] Nervenheilkunde 22:93-97, 2003.
27. Findling RL, McNamara NK: Atypical antipsychotics in the treatment of children and adolescents: Clinical applications. J Clin Psychiatry 65(Suppl 6):30-34, 2004.
28. Findling RL, McNamara, NK, Gracious BL: Paediatric uses of atypical antipsychotics. Expert Opin Pharmacother 1:935-945, 2000.
29. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ: Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999. (Pubitemid 29353030)
30. Gässler N, Peuschel T, Pankau R: Pediatric reference values of estradiol, testosterone, lutropin, follitropin and prolactin. Clin Lab 46:553-560, 2000. (Pubitemid 30943055)
31. Greenspan SL, Neer RM, Ridgway EC, Klibanski A: Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777-782,1986.
32. Greenspan SL, Oppenheim DS, Klibanski A: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526-531, 1989.
33. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management." Drugs 64:2291-2314, 2004.
34. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS: Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects. Psychoneuroendocrinology 28(Suppl 1):53-67, 2003. (Pubitemid 36015661)
35. Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE: The role of tamoxifen in the management of gynaecomastia. Breast 15:276-280, 2006.
36. Hardan A, Johnson K, Johnson C, Hrecznyj B: Case study: Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 35:1551-1556, 1996. (Pubitemid 26360942)
37. Hediger ML, England LJ, Molloy CA, Yu KF, Manning-Courtney P, Mills JL: Reduced bone cortical thickness in boys with autism or autism spectrum disorders. J Autism Dev Disord 38:848-856, 2008. (Pubitemid 351601312)
38. Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR: Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:885-892, 2005. (Pubitemid 43042979)
39. Howard L, Kirkwood G, Leese M: Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190:129-134, 2007. (Pubitemid 46256188)
40. Howlett TA, Wass JA, Grossman A, Plowman PN, Charlesworth M, Touzel R: Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: Response to medical therapy. Clin Endocrinol (Oxf ) 30:131-140, 1989. (Pubitemid 19063217)
41. Hugenholtz GWK: Antipsychotic in daily clinical practice: Patterns, choices and consequences. Universiteit Utrecht. Utrecht, Utrecht. Doctor 172, 2005.
42. Kawano Y, Kamihigashi S, Nakamura S, Miyakawa I: Delayed puberty associated with hyperprolactinemia caused by pituitary microadenoma. Arch Gynecol Obstet 264:90-92, 2000. (Pubitemid 30745859)
43. Knegtering H: Antipsychotic treatment and sexual functioning: Role of prolactin. Rijksuniversiteit Groningen. Groningen, Rijksuniversiteit Groningen. Doctor 169, 2003.
44. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ: What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 28(Suppl 2):109-123, 2003.
45. Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H: A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24:56-61, 2004. (Pubitemid 38139316)
46. Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D: A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther 32:315-326, 2006. (Pubitemid 43995227)
47. Langer G, Sachar EJ, Halpern FS, Gruen PH, Solomon M: The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men. J Clin Endocrinol Metab 45:996-1002, 1977. (Pubitemid 8238613)
48. Lenton EA, Brook LM, Sobowale O, Cooke ID: Prolactin concentrations in normal menstrual cycles and conception cycles. Clin Endocrinol (Oxf ) 10:383-391, 1979. (Pubitemid 10171762)
49. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M: Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16:575-587, 2006. (Pubitemid 44737212)
50. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA: Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140-147, 2002. (Pubitemid 38338162)
51. Malone RP, Delany MA, Hyman SB, Cater JR: Ziprasidone in adolescents with autism: An open-label pilot study. J Child Adolesc Psychopharmacol 17:779-790, 2007. (Pubitemid 351158593)
52. Marken PA, Haykal RF, Fisher JN: Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11:851-856, 1992.
53. Masi G, Cosenza A, Mucci M: Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 11:389-394, 2001. (Pubitemid 34117288)
54. Masi G, Cosenza A, Mucci M, Brovedani P: A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64:1039-1047, 2003. (Pubitemid 37158249)
55. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000. (Pubitemid 30305366)
56. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002. (Pubitemid 34815353)
57. Meaney AM, O'Keane V: Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. J Psychopharmacol 17:455-458, 2003. (Pubitemid 38076344)
58. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184:503-508, 2004. (Pubitemid 38725710)
59. Meaney AM, O'Keane V: Bone mineral density changes over a year in young females with schizophrenia: Relationship to medication and endocrine variables. Schizophr Res 93:136-143, 2007.
60. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 54:719-723, 2003. (Pubitemid 36752965)
61. Misra M, Papakostas GI, Klibanski A: Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65:1607-1618; quiz 1590, 1760-1761, 2004.
62. Molitch ME: Medication-induced hyperprolactinemia. Mayo Clin Proc 80:1050-1057, 2005.
63. Nakonezny PA, Byerly MJ, Rush AJ: The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 33:203-216, 2007
64. O'Keane V, Meaney AM: Antipsychotic drugs: A new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25:26-31, 2005.
65. Pappagallo M, Silva R: The effects of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 14:359-371, 2004. (Pubitemid 39473122)
66. Papparigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C: Amisulpiride-induced hyperprolactinaemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 31:92-96, 2007. (Pubitemid 44959254)
67. Patton ML, Woolf PD: Hyperprolactinemia and delayed puberty: A report of three cases and their response to therapy. Pediatrics 71:572-575, 1983.
68. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M: Longterm use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16:260-272, 2006. (Pubitemid 43902423)
69. Sack J, Friedman E, Tadmor R, Sahar A, Katznelson D: Growth and puberty arrest due to prolactinoma. Acta Paediatr Scand 73:863-867, 1984. (Pubitemid 15209692)
70. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004. (Pubitemid 39473121)
71. Sallee FR, Dougherty D, Sethuraman G, Vrindavanam N: Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol Psychiatry 40:1044-1050, 1996. (Pubitemid 26391682)
72. Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT: Psychotropic medication in children: A study from the Netherlands. Pediatrics 108:E25, 2001.
73. Seeman P, Bzowej NH, Guan HC, Bergeron C, Becker LE, Reynolds GP: Human brain dopamine receptors in children and aging adults. Synapse 1:399-404, 1987.
74. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424, 2001. (Pubitemid 34117291)
75. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004. (Pubitemid 38068023)
76. Simeon J, Lawrence S, Simeon S: Effects of pimozide on prolactin in children [proceedings]. Psychopharmacol Bull 15:40-42, 1979. (Pubitemid 9159194)
77. Siris SG, Siris ES, van Kammen DP, Docherty JP, Alexander PE, Bunney WE: Effects of dopamine blockade on gonadotropins and testosterone in men. Am J Psychiatry 137:211-214, 1980.
78. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002. (Pubitemid 38338050)
79. Staller J: The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 16:317-326, 2006. (Pubitemid 43902428)
80. Stevens JR, Kymissis PI, Baker AJ: Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 15:893-900, 2005.
81. Suwa S, Naruse H, Ohura T, Tsuruhara T, Takesada M, Yamazaki K: Influence of pimozide on hypothalamo-pituitary function in children with behavioral disorders. Psychoneuroendocrinology 9:37-44, 1984. (Pubitemid 14110438)
82. Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L: Prolactin release in children treated with risperidone: Impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 27:52-57, 2007.
83. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002. (Pubitemid 38338050)
84. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663-667, 2003.
85. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245, 1999. (Pubitemid 30005078)
86. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K: Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 157:17-25, 2003. (Pubitemid 36343413)